Pharmaceutical equivalence and similarity studies of glibenclamide tablets

Luis Alberto Sánchez-Nava; Urias Bautista-Sánchez; Ana Luisa Robles-Piedras

doi:10.30574/gscbps.2019.7.1.0053

Authors

Luis Alberto Sánchez-Nava Academic Area of Pharmacy. Institute of Health Sciences, Autonomous University of the State of Hidalgo. Ex-Hacienda La Concepción Circuit, Km. 1.5, San Agustín Tlaxiaca, Hidalgo. c.p. 42160, Mexico.
Urias Bautista-Sánchez Academic Area of Pharmacy. Institute of Health Sciences, Autonomous University of the State of Hidalgo. Ex-Hacienda La Concepción Circuit, Km. 1.5, San Agustín Tlaxiaca, Hidalgo. c.p. 42160, Mexico.
Ana Luisa Robles-Piedras Academic Area of Pharmacy. Institute of Health Sciences, Autonomous University of the State of Hidalgo. Ex-Hacienda La Concepción Circuit, Km. 1.5, San Agustín Tlaxiaca, Hidalgo. c.p. 42160, Mexico.

DOI:

https://doi.org/10.30574/gscbps.2019.7.1.0053

Keywords:

Glibenclamide, Dissolution, Pharmaceutical equivalence

Abstract

The in vitro dissolution is the physicochemical test most used to estimate the release of the drug from the pharmaceutical form. Due to the close relationship between the dissolution rate of the drug in vitro and the absorption in vivo, the dissolution study is considered as the necessary and sufficient criterion to allow the commercialization of a pharmaceutical product. In this study, the similarity of the dissolution profiles of different products containing glibenclamide used in the Mexican Health Sector was compared. The dissolution profiles of 7 generic products were constructed and analyzed and compared with the innovative drug. The quality control carried out showed that one generic product did not comply with the specifications. Two products showed no difference in the percentage dissolved compared to the reference product; however, none of the products presented a parallel behavior to the innovator. Only one of the seven pharmaceutical products used in the Health Sector met the interchangeability criteria. Properly controlled bio-equivalence studies are strongly recommended to further investigate the potential inequivalence of the tested products.

Metrics

Metrics Loading ...

References

Blume H, Ali SL and Siewert M. (1993). Pharmaceutical quality of glibenclamide products a multinational postmarket comparative study. Drug Development and Industrial Pharmacy, 19(20), 2713-2741.

Coppack S, Lant A and Rodgers A. (1990). Pharmacokinetic and pharmacodynamics studies of glibenclamide in non-insulin dependent diabetes mellitus. British Journal of Clinical Pharmacology, 29(6), 673-684.

Chalk JB, Patterson M, Smith MT and Eadie MJ. (1986). Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. European Journal of Clinical Pharmacology, 31(2), 177-182.

Kathri J, Qassim S, Abed O, Abram B, Al-Lami A and Massad SA. (2001). A novel extractionless HPLC Fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. Journal of Pharmacy & Pharmaceutical Sciences, 4(2), 201-206.

Idries AM, Ahmed ME, Mudawi ME and Ibrahim KE. (2012). Interchangeability and comparative effectiveness between micronized and non-micronized products of glibenclamide tablets. Sudan Journal of Medical Sciences, 7(3), 153-159.

Marchetti P, Navalesi R. (1989). Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clinical Pharmacokinetics, 16(2), 100-128.

Boix A. Sustitución y selección de equivalentes terapéuticos. (1996). Farmacia Hospitalaria, 20(6), 351-358.

García J, Salcedo A, Covarrubias V, Colunga C and Milke M. (2004). Diabetes mellitus tipo 2 y ejercicio físico. Resultados de una intervención. Revista Médica del IMSS, 40(5), 395-404.

Norma Oficial Mexicana NOM-177-SSA1-2013, que establece las pruebas y procedimientos para demostrar que un medicamento es intercambiable. Diario Oficial de la Federación 20/09/2013.

Farmacopea de los Estados Unidos Mexicanos. Comisión Permanente de Farmacopea de los Estados Unidos Mexicanos. 9ª edición. Secretaria de Salud. México 2009. p.:309-10; 1040-1.

Mauger J, Chilko D and Howard S. (1986). On the analysis of dissolution data. Drug Development and Industrial Pharmacy, 12(7), 969-992.

Dressman J and Reppas C. (2000). In vitro -in vivo correlations for lipophilic, poorly water-soluble drugs. European Journal of Pharmaceutical Sciences, 11(S2), 573-580.

Nokhodchi A, Javadzadeh Y, Isasi-Shadbad MR and Baezegar-Jalali M. (2005). The effect of type concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. Journal of Pharmaceutical Sciences, 8(1), 18-25.